ASCO GU 2020 expert interviews

ASCO expert Robert Dreicer shares his views on the updates from the CARD, TITAN, and STOMP prostate cancer trials presented at ASCO GU 2020 (3:07).

Read more about the STOMP trial and the CARD trial

Petros Grivas explains why the story of PARP inhibitors in advanced urothelial carcinoma is not quite finished yet despite the negative results of the ATLAS trial of rucaparib in this setting (4:45).

Shilpa Gupta gives the top-line results of their trial investigating the addition of nivolumab to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. She also discusses the neoadjuvant NEO-BLADE study presented at the conference and speculates on the reasons for the differing results (3:16).

Hans Hammers discusses the RADVAX RCC trial combining dual checkpoint blockade and stereotactic body radiotherapy for the treatment of metastatic renal cell carcinoma, and also comments on the similar NIVES study (2:16).

Read the accompanying news story

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Toni Choueiri reports on the advanced renal cell carcinoma cohort of the phase 1/2 trial of MK-6482, a first-in-class inhibitor of hypoxia-inducible factor (HIF)-2α (2:36).

Ziad Bakouny presents data on cytoreductive nephrectomy outcomes in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors that suggest there may yet be a role for the procedure in certain patients (4:43).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Read the accompanying news story

Axel Merseburger takes us through the studies that caught his attention at ASCO GU 2020, including the NIMBUS trial and first-in-human study of the HIF-2α inhibitor MK-6482 (3:24).

Neeraj Agarwal outlines the findings of the metastatic castration-resistant prostate cancer cohort of the COSMIC-021 trial of cabozantinib plus atezolizumab (3:21).

Read the accompanying news story

Daniel Geynisman discusses the potential for the novel tyrosine kinase inhibitor sitravatinib and the HIF-2α inhibitor MK-6482 to change the treatment paradigm in advanced clear-cell renal cell carcinoma (4:47).

Jonathan Rosenberg provides an update on the EV-103 trial of combined enfortumab vedotin plus pembrolizumab for the first-line treatment of cisplatin-ineligible advanced urothelial carcinoma (3:40).

Read the accompanying news story

Ziad Bakouny outlines his research into the determinants of the poor prognosis and response to immune checkpoint inhibitors seen in patients with sarcomatoid and rhabdoid renal cell carcinoma (4:14).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Pavlos Msaouel reports on the efficacy and toxicity of combined treatment with the novel tyrosine kinase inhibitor sitravatinib and nivolumab in people with advanced renal cell carcinoma (4:53).

Yann-Alexandre Vano describes a translational analysis of the NIVOREN GETUG-AFU 26 trial to identify biomarkers associated with outcomes in nivolumab-treated patients with metastatic clear cell renal cell carcinoma (3:29).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA